GPC1抗体—艾普蒂 新品

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-2: HEPG2 and Jurkat cell, Primary antibody: P05663(GPC1 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 40 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P05663(GPC1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P05663(GPC1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

**Background of GPC1 Antibody**

Glypican-1 (GPC1), a member of the glypican family of heparan sulfate proteoglycans, is a cell surface protein anchored via a glycosylphosphatidylinositol (GPI) linkage. It plays a regulatory role in cell signaling by modulating interactions between growth factors, morphogens (e.g., FGF, Wnt), and their receptors. GPC1 is broadly expressed in embryonic tissues but shows restricted expression in adults, with elevated levels observed in certain cancers, including pancreatic, breast, and glioblastoma. Its involvement in oncogenic signaling pathways, such as Wnt and Hedgehog, has linked GPC1 to tumor progression, metastasis, and angiogenesis.

GPC1 antibodies are tools designed to target this protein for research, diagnostic, or therapeutic purposes. In diagnostics, GPC1-positive exosomes in bodily fluids (e.g., blood) have emerged as non-invasive biomarkers for early cancer detection, particularly in pancreatic cancer. Therapeutically, GPC1 antibodies are explored for targeted drug delivery or as inhibitors to block oncogenic signaling. For instance, antibody-drug conjugates (ADCs) or CAR-T cells targeting GPC1 are under preclinical investigation.

Research using GPC1 antibodies has also clarified its structural and functional roles, such as its core protein interactions and heparan sulfate chain-mediated ligand binding. Challenges remain in specificity and minimizing off-target effects, but ongoing studies aim to optimize GPC1-based strategies for clinical translation. Overall, GPC1 antibodies represent a promising avenue in both understanding cancer biology and advancing precision oncology.